Radiation-guided drug delivery systems

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 283-288

  Stacy, Donnie R ^a   Lu, Bo ^a   Hallahan, Dennis E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

131I; Alemtuzumab ; Bexxar ; Biapcitide; Boron neutron capture therapy; Genetherapy; Herceptin ; Hyperthermia; Microbubbles; Micromagnets; Nanoparticles; Neoantigens; Photodynamic therapy; Radioimmunoconjugates; Recombinant peptide technology; Rituxan ; TNF erade; X rays

Indexed keywords

AMINOLEVULINIC ACID; ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; CONTRAST MEDIUM; CYTOTOXIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN RECEPTOR; HALOGEN; HYPERICIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; IRON; LIGAND; LIPOSOME; NANOPARTICLE; PADGEM PROTEIN; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL STUDY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG TARGETING; GENE INDUCTION; GENE THERAPY; HUMAN; HYPERTHERMIC THERAPY; MAGNETIC FIELD; MAGNETISM; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; NONHUMAN; PHOTODYNAMIC THERAPY; RADIATION ENERGY; RADIATION FIELD; RADIOIMMUNOTHERAPY; REVIEW; SKIN PENETRATION; TISSUE DISTRIBUTION; TOXICITY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; ULTRASOUND THERAPY; X RAY;

EID: 1842639009     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.283     Document Type: Review

References (52)

1. Salvatori M, Rufini V, Garganese MC, Di Guida D. Radioiodine therapy in differentiated thyroid carcinoma. Rays 25(2), 221-238 (2000).
2. Ross J, Gray K, Schenkein D et al. Antibody-based therapeutics in oncology. Expert Rev. Anticancer Ther. 3(1), 107-127 (2003).
3. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I-131 tositumomab. Semin. Oncol. 30(2 Suppl. 4), 31-38 (2003).
4. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 21(9), 1874-1881 (2003).
5. Nemecek ER, Matthews DC. Use of radiolabeled antibodies in the treatment of childhood acute leukemia. Pediatr. Transplant 7(Suppl. 3), 89-94 (2003).
6. Begent RH. Targeting cancer therapy. Br. J. Cancer 80(Suppl. 1), 104-109 (1999).
7. Vose JM. Immunotherapy for non-Hodgkin's lymphoma. Clin. Oncol. 5(4), 1-11 (2002).
8. Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: The Seattle experience. Ann. Hematol. 79, 175-182 (2000).
9. Ram S, Buchsbaum DJ. Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice. Cancer 73(3 Suppl.), 808-815 (1994).
10. Weiner GJ, Kahn D, Jochimsen PR, Bevering CG, Kisker MA. Radiolabeled antibody imaging of patients with potentially resectable colorectal adenocarcinoma. Cancer Invest. 12(2), 111-120 (1994).
11. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380 (1998).
12. Hallahan DE, Mauceri HJ, Seung LP et al. Spatial and temporal control of gene therapy by ionizing radiation. Nature Med. 1, 786-791 (1995).
13. Kasahara N, Dozy A, Kan Y. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376 (1994).
14. Cheresh D. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor. Proc. Natl Acad. Sci. 84, 6471-6475 (1987).
15. Wickham T, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 2, 750-756 (1995).
16. 90Y-labeled C110 anti-CEA immunotoxin: A potent therapeutic immunoconjugate for human colon cancer. Cancer Res. 51, 255-260 (1991).
17. Kirpotin D, Park JW, Hong K et al. Sterically stabilized antiHER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 36(1), 66-75 (1997).
18. Hellstrom I, Trail P, Siegall C, Firestone R, Hellstrom K. Immunoconjugates and immunotoxins for therapy of solid tumors. Cancer Chemother. Pharmacol. 38, 35-36 (1996).
19. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim. Biophys. Acta 1333, 1-6 (1997).
20. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells 3, 77-85 (1991).
21. Jain RK. The Eugene M Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4, 1-23 (1997).
22. Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. Ann. NY Acad. Sci. 618, 367-382 (1991).
23. Baillie C, Winslet M, Bradley N. Tumour vasculature: A potential therapeutic target. Br. J. Cancer 72, 257-267 (1995).
24. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
25. Burg M, Pasqualini R, Ruoslahti E, Stallcup W. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59, 2869-2874 (1999).
26. Ellerby H, Ruoslahti E, Pasqualini R. Anticancer activity of targeted pro-apoptotic peptides. Nature Med. 5, 1032-1038 (1999).
27. Fox S, Harris A. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy. Invest. New Drugs 15, 15-28 (1997).
28. Molema G, de Leij L, Meijer D. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14, 2-10 (1997).
29. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763 (1995).
30. McGinity JW, O'Donnell PB. Preparation of nanoparticles by the solvent evaporation technique. Adv. Drug Deliv. Rev. 28(1), 25-42 (1997).
31. Llovet JM, Real MI, Montana X et al. Arterial chemoembolization vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma. Lancet 395, 1734-1739 (2002).
32. Shackley DC, Briggs C, Whitehurst C et al. Photodynamic therapy for superficial bladder cancer. Expert Rev. Anticancer Ther. 1(4), 523-530 (2001).
33. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: Past, present and future. Urol. Res. 29(6), 396-405 (2001).
34. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: A useful and realistic option. Technol. Cancer Res. Treat. 2(1), 65-76 (2003).
35. Capella MA, Capella LS. A light in multi-drug resistance: photodynamic treatment of multi-drug resistant tumors. J. Biomed. Sci. 10(4), 361-366 (2003).
36. Barth RF, Soloway AH, Goodman JH et al. Boron neutron capture therapy of brain tumors: An emerging therapeutic modality. Neurosurgery 44(3), 433-451 (1999).
37. Diaz AZ. Assessment of the results from the Phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neurooncol. 62(1-2), 101-109 (2003).
38. Harling OK, Riley KJ. Fission reactor neutron sources for neutron capture therapy: A critical review. J. Neurooncol. 62(1-2), 7-17 (2003).
39. Nakagawa Y, Pooh K, Kobayashi T et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neurooncol. 62(1-2), 87-99 (2003).
40. Bozzetti F, Vaglini M, Deraco M. Intraperitoneal hyperthermic chemotherapy in gastric cancer: Rationale for a new approach. Tumori 84(4), 483-488 (1998).
41. Witkamp AJ, de Bree E, van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic ip. chemotherapy. Cancer Treat. Rev. 27(6), 365-374 (2001).
42. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T. Local drug and gene delivery through microbubbles. Prog. Cardiovasc. Dis. 44(1), 45-54 (2001).
43. Rice RJ, Kaul S. Contrast ultrasound targeted drug and gene delivery: An update on a new therapeutic modality. J. Cardiovasc. Pharmacol. Ther. 7(3), 171-180 (2002).
44. Hallahan DE, Vokes EE, Rubin SJ et al. Phase I dose-escalation study of tumor necrosis factor-α and concomitant radiation therapy. Cancer J. Sci. Am. 1(3), 204 (1995).
45. Monroe WT, McQuain MM, Chang MS, Alexander JS, Haselton FR. Targeting expression with light using caged DNA. J. Biol. Chem. 274(30), 20895-20900 (1999).
46. Hallahan DE, Geng L, Cmelak AJ et al. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J. Control Release 74(1-3), 183-191 (2001).
47. Hallahan DE, Qu S, Geng L et al. Radiation-mediated control of drug delivery. Am. J. Clin. Oncol. 24(5), 473-480 (2001).
48. Hallahan DE, Geng L, Qu S et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3, 63-74 (2003).
49. Jacob G, Ciochina AD, Bredetean O. Magnetic carrier method: an expectation for antitumoral therapy. Rev. Med. Chir. Soc. Med. Nat. Iasi 105(4), 815-821 (2001).
50. Moroz P, Jones SK, Winter J, Gray BN. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model. J. Surg. Oncol. 78(1), 22-29 (2001).
51. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: Current status and future directions. Int. J. Hyperthermia 18(4), 267-284 (2002).
52. Hilger I, Hiergeist I, Hergt R, Winnefeld K, Schubert H, Kaiser WA. Thermal ablation of tumors using magnetic nanoparticles: An in vivo feasibility study. Invest. Radiol. 37(10), 580-586 (2002).